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Objective. CIGB-228 is a novel therapeutic vaccine consisting of HLA-restricted HPV16 E7 epitope adjuvated with VSSP. This trial
was designed to evaluate the toxicity, safety, immunogenicity, HPV clearance, and lesion regression. Methods. Seven women were
entered. All were HLA-A2 positive, had biopsy-proven high-grade CIN, histologically positive for HPV16, and beared persistent
postbiopsylesionsvisiblebydigitalcolposcopy.HLA-A2womenwithbiopsy-provenhigh-gradeCIN,HPV16-positive,andbeared
persistent postbiopsy lesions visible by digital colposcopy were vaccinated. One weekly injections of CIGB-228 vaccine was given
for four weeks. Then, loop electrosurgical excision procedure (LEEP) of the transformation zone was performed. Study subjects
werefollowedfor1yearafterLEEP.Results.Notoxicitybeyondgrade1wasobservedduringandafterthefourvaccinations.Fiveof
seven women had complete and partial regression. Cellular immune response was seen in all patients. HPV was cleared in three of
the patients with complete response. Conclusion. CIGB-228 vaccination was well tolerated and capable to induce IFNγ-associated
T-cell response in women with high-grade CIN. In several patients, lesion regression and HPV clearance were observed.
1.Introduction
The human papillomaviruses (HPVs), especially the high-
risk types (HPV types 16 and 18) have been implicated in the
development of high-grade cervical intraepithelial neoplasia
(CIN II/III) and invasive cervical cancer [1, 2].
Preventive strategies utilizing vaccines directed against
structural components of this virus have been approved.
While prevention of HPV infection is an important goal for
future generations of women, such intervention will useless
to the millions already infected with high risk genotypes.
Low-grade lesions (CIN I) usually clear spontaneously,
whereas high-grade CIN II and III often persist and may
progress to carcinoma [3, 4]. Current treatment strategies
such as a loop electrosurgical excision procedure (LEEP) or
cone biopsy of the cervix are aimed to excision of visible
lesions and may eliminate HPV-infected cells and associ-
ated disease. Such ablative procedures may activate cellular
immune responses to the associated HPV antigens. However,
when the size of the lesion is large treatment with LEEP may
be incomplete which leads to the permanence of positive
margins and the persistence of high-grade lesions. Moreover,2 ISRN Obstetrics and Gynecology
Table 1: Results of detection of HPV16 correlated with clinical and immune response.
Patients Age HPV 16 before
vaccine HPV 16 prior to LEEP Initial histology End histology after
LEEP
Clinical
status
Immune
response
01 43 + + CIN II Koilocytosis CR +
02 38 + + CIN III CIN III SD +
03 24 + + CIN III CIN II PR +
04 25 + − CIN II Koilocytosis CR +
05 26 + − CIN III Koilocytosis CR +
06 25 + − CIN III Negative CR +
07 25 + + CIN III CIN III SD +
Note: All patients were positive for HLA-A2.
Initialhistologywasbycervicalbiopsypriortothestudy.EndhistologywasbyLEEPatterminationofthestudy(90daysaftertheﬁrstvaccineadministration).
Abbreviations
CIN II-III: cervical intraepithelial neoplasia, grade II or III.
CR: complete response; PR: partial response; SD: stable disease.
patients with CIN who have undergone ablative surgery or
even a hysterectomy may still have HPV infection [5], which
may result in recurrent or persistent CIN. These patients
require repetitive invasive procedures for treatment. This can
be problematic for women who desire future fertility due to
distortion of the cervix after invasive interventions and also
for preterm birth [6].
Vaccination strategies that boost natural immunity to
HPV might allow clearance of the virus leading to resolution
of dysplastic lesions. This could avoid the need for invasive
treatment and may lead to a lower risk of recurrence. Various
vaccines aimed at inducing regression in women with biopsy
proven CIN II/III have been studied. The most frequently
targeted antigens are the E6 and E7 proteins, because they
are oncogenic and sustained expression is required for the
maintenance of the cancerous phenotype. Their immuno-
genicity has rendered these HPV proteins an attractive target
for immunization strategies to prevent cervical carcinoma
[1, 2]. However, these vaccines have generally not been
eﬀective enough to produce a real tumor rejection (for
review, see [7, 8]). As with every biological system, tumors
use opportunistic and redundant mechanisms to guarantee
their survival and development. The robustness of these
processes makes cancer immunotherapy a real challenge.
The success of cancer immunotherapy will not depend only
on optimal tumor-associated antigen but also of the use of
appropriate adjuvants, while being nontoxic and safe (for
review, see [9]).
A new adjuvant approach has been previously developed
in which gangliosides are incorporated into the N. menin-
gitides outer membrane complex to form a nanoparticulate
of very small size proteoliposomes (VSSP) [10]. Vaccination
with the VSSP adjuvated HPV16 E7 (49–57) minimal CTL
peptide protected mice against the HPV16 tumor model TC-
1 challenge, induced regression of established tumors as well
as E7-speciﬁc CD8+ T-cell responses [11].
On the basis of this preclinical rationale, “ﬁrst-in-
human” clinical trial with the CIGB-228 vaccine containing
HLA-restricted HPV16 E7 epitope known to be recognized
by CTLs (E7 peptide 86–93) [12] adjuvated with VSSP
was done in patients with CIN II/III. In addition to the
toxicity and tolerability of the CIGB-228 vaccine, immune,
virological and clinical response end points were assessed.
2.MaterialandMethods
2.1. Patient Eligibility. HLA-A2-positive patients, 18-to-65
years-old with histological conﬁrmed HPV16-positive CIN
II/III, with a larger diameter ≥3mm by videocolposcopy
were recruited at specialized services from seven gyneco-
obstetric hospitals throughout Havana and other provinces
after oral and written informed consent (Table 1). They
were then evaluated at the National Reference Center for
Cervical Cancer at the “Ramon Gonzalez Coro” Havana
Hospital, where the eligibility criteria were veriﬁed. Eli-
gibility also required the following criteria: leukocytes >3
× 109/L, lymphocytes >1 × 109/L, thrombocytes >100 ×
109/L, and hematocrit >30%. Exclusion criteria were to
have received any immunomodulator treatment up to 3
months before inclusion, psychiatric dysfunctions, preg-
nancy, and breastfeeding, decompensate chronic diseases
suchasasthma,epilepsy,autoimmune,orimmunodeﬁciency
diseases, hypertension, anemia, acute systemic or genital
tract infections, and renal, hepatic, and cardiovascular
disorders.
2.2. Study Design. The study followed the principles of the
Declaration of Helsinki for investigations in humans. It was
approved by the Ethics and Scientiﬁc Committees of the par-
ticipant institutions and by the Cuban Regulatory Authority.
This was a single-arm, open, and uncontrolled study. The
main purpose of the trial was to evaluate the product’s safety
during local and systemic adverse events. Sample size was
previewedasbetween7and10patients.ThisNrangeassured
that if no severe adverse reaction appeared, the probability of
its occurrence would be less than 20%, with an 80%–90%
conﬁdence interval. Patients received four vaccinations. The
vaccine was administered subcutaneously at 1-week intervals
(Figure 1). Subjects were subjected to colposcopy monthly
and LEEP excision of lesions in the cervix 60 days afterISRN Obstetrics and Gynecology 3
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Figure 1: Schematic overview of vaccination scheme.
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Figure 2: Schematic overview of the clinical trial procedure.
completion of the immunization protocol (Figure 2).
2.3. Composition of the Vaccine. The CIGB-228 vaccine
consists of two components. The HPV16 E7(86–93) peptide
was synthesized and supplied by the Center for Genetic
Engineering and Biotechnology (CIGB) in 0.12mg vials,
as a lyophilized powder. VSSP was produced and supplied
by the Center of Molecular Immunology in 0.8mg/0.5mL
vials. Prior to the vaccination, the HPV16 E7(86–93) synthetic
peptide was reconstituted with water for injection and then
adjuvated with VSSP. One dose of the CIGB-228 vaccine
contained 0.1mg of peptide and 0.16mg of VSSP in a total
volume of 0.5mL.
2.4. Clinical Assessment. Subjects underwent a general phys-
ical, cytological, and a colposcopic examinations monthly
and cervical biopsy prior to and at termination of the study
by LEEP (90 days after the ﬁrst vaccine administration).
Blood samples were drawn for routine safety analysis prior
to and 1 week after each vaccine administration and for
immunological analysis prior to each vaccination and two
weeks after the last dose (Figure 1). Patients were tested for
pregnancy at each visit. Additionally, patients were followed
clinically and colposcopically at 3, 6, 9, and 12 months after
LEEP (Figure 2). Since the main purpose of the trial was
to evaluate the product’s safety, local and systemic adverse
events were carefully assessed. Systemic toxicity was evalu-
ated for 24 hours after each CIGB-228 vaccination, including
continuous cardiovascular monitoring, temperature, respi-
ratory frequency, and blood pressure measurements 30min
after each injection, then every hour during 4 hours. Patients
completed diary cards of adverse events as auto report
over the seven days following each vaccine administration.
The medical terminology used for AE and their severity
classiﬁcation (in grades) were those of the Cancer Therapy4 ISRN Obstetrics and Gynecology
Evaluation Program, Common Terminology Criteria [13].
Colposcopical evaluations were done using a video
colposcopy device (Mediscope, Medison, Korea) with a
calibrated rack to standardize imaging distance and illumi-
nation. Lesions were examined by two diﬀerent specialists
after applying 5% acetic acid for 3min. They were described
according to the Barcelona 2002 classiﬁcation [14], and their
morphometric analysis was done with validated software for
quantitative digital image evaluation (MADIP V.4; Institute
of Cybernetics, Mathematics, and Physics, Havana).
Histological analyses were performed on colposcopically
directed biopsies from abnormal areas taken before treat-
ment and afterwards in the LEEP specimen. Permanent sec-
tions were subsequently prepared, stained with hematoxylin-
eosin, and ﬁnally reviewed by two diﬀerent pathologists who
classiﬁed the lesions according to the FIGO classiﬁcation.
2.5. Response Criteria and Clinical Activity. The total lesion
area (TLA) was the parameter evaluated for colposcopical
response. Response was deﬁned according to the RECIST
criteria [15]. The percentage of decrease was measured as
%decrease =
TLAinitial −TLAﬁnal
TLAinitial
×100. (1)
Complete response was considered as disappearance of all
initial TLA; partial response if at least a 30% decrease of the
initial TLA; progressive disease meant at least a 20% increase
of the initial TLA and as stable disease if a reduction or an
increase of the TLA compared to the initial value that is not
enough for classiﬁcation of the outcome as partial response
or progressive disease.
The histological response was based on the lesions phase
changes. A complete response was deﬁned as the absence of
high-grade lesions after vaccination, partial response when
a downstaging of the high-grade lesion occurred; stable
disease when a lesion remains at the same initial stage, and
progression if there was upstaging.
2.6. HLA Testing. HLA-A2 allele was performed by PCR-SSP
typing of HLA class I allele method [16].
2.7. Technique for HPV Detection. The presence of HPV
DNA in biopsies was examined prior to and at termination
of the study (90 days after the ﬁrst vaccine administration)
by PCR using a pair of L1-consensus primers (GP5+/GP6+)
[17]. The HPV DNA detection limit was about 310 viral
copies. Additional PCR with speciﬁc HPV16 primers was
performed [18] and HPV DNA levels were normalized with
those corresponding to β-globin as housekeeping gene.
2.8. Peptides. Peptides used for in vitro studies were synthe-
sized at the CIGB. The peptide sequences were from HPV16
E7, encompassing aminoacids 11–20, 82–90, and 86–93, and
inﬂuenza M1 peptide (GILGFVFTL, aa58–66).
2.9. Lymphocytes. Peripheral blood mononuclear cells
(PBMC) were isolated from fresh K3-EDTA blood samples
within 2h after sample collection using Ficoll density gra-
dient according to the manufacturer (Bio-Sciences AB) and
seeded at 5–10×106 cells/mL in freezing medium consisting
of nine parts fetal bovine serum (FCS; Hyclone,) and one
part dimethylsulfoxide (Sigma). PBMC were stored over-
night in 1◦C freezing containers (Nalgene Nunc Interna-
tional) at −80◦C and then transferred into liquid nitrogen
until use.
2.10. HPV-Speciﬁc T-Cell Immunity Monitoring. Brieﬂy, cry-
opreserved pre- and postvaccine PBMC were thawed quickly
in a 37◦C water bath. Then, cells were washed twice with
phosphate buﬀer saline (PBS) and seeded in three replicate
wells at a density of 2 × 105 cell/well in 100μLo fR P M I
medium (Sigma) enriched with 10% of human AB serum
(Sigma) and 50μL/well of 10μg/mL of indicated HPV16 E7
peptides,10μg/mLofinﬂuenzaM1peptideand0.1μg/mLof
anti-CD3 mAb CD3-2 (positive control) or medium (nega-
tive control) as corresponded in a multiscreen 96-well PVDF
plate (Mabtech AB) coated with an IFN-γ-catching antibody
(Mabtech AB). After two days of incubation at 37◦C, the
ELISPOT was performed according to the manufacturer’s
instructions (Mabtech AB). Spots were counted with a fully
automated computer-assisted video-imaging analysis system
(Carl Zeiss Vision). A positive response to antigen was
deﬁned as >20 spots (IFN-γ-producing cells)/106 PBMCs
in response to antigen (after subtraction of background).
A positive response after vaccination was recorded if the
frequency of IFN-γ-producing cells postvaccination was
greater than twice the prevaccination response to an antigen.
3. Results
3.1. Study Population. Between October 2007 and February
2008, 7 women were included. Clinical and demographic
characteristics of the study patients are shown in Table 1.
Age ranged from 24 to 43 years (median 29). All patients
had high-grade CIN conﬁrmed on their histological pre-
study and lesion areas between 30 and 638mm2 (Table 2).
Moreover,allwomenwereHPV16andHLA-A2positive.The
treatmentschedule wascompleted in allpatients, whichwere
also evaluated one year after their LEEP for recurrence.
3.2. Adverse Events. Table 3 lists all adverse events assessed
as possibly being associated with the vaccine. All patients
reported local pain at the vaccination site and 6 patients
reported burning sensation. Other events were reported
with low frequencies as local redness and swelling. Systemic
adverse events, including fever, tremors, and cramps were
registered in few cases. No vaccine-related events exceeded
grade 1 (mild) and recovered spontaneously. One patient
reported lower abdominal pain as a result of urinary sepsis.
This event was considered to be unrelated to the vaccination.
There were no late adverse events either.
3.3. Clinical Evaluations. Individual results are shown in
Tables 1 and 2. TLA decreased in all patients at colposcopyISRN Obstetrics and Gynecology 5
Table 2: Colposcopic evaluation of patients.
TLA (mm2) Patients
01 02 03 04 05 06 07
Initial 244.93 493.68 608.98 638.98 481.71 30.8 291.96
1 month 0 (100%) 462.46 (6.32%) 486.72 (20.07%) 0 (100%) 75.70 0 (100%) 182.10 (37.62%)
2 months 0 (100%) 441.12 (10.64%) 381.8 (37.3%) 0 (100%) 48.15 0 (100%) 149.78 (48.69%)
3 months 0 (100%) 403.2 (18.32%) 286.61 (52.93%) 0 (100%) 0 (100%) 0 (100%) 104.73 (64.12%)
Responsestatus CR SD PR CR CR CR PR
Abbreviations
TLA: total lesion area.
TLA: total lesion area.
Complete response (CR) was considered as disappearance of all initial TLA; (PR) partial response if at least a 30% decrease of the initial TLA; progressive
disease (PD) meant at least a 20% increase of the initial TLA and as stable disease (SD) if a reduction or an increase of the TLA compared to the initial value
that is not enough for classiﬁcation of the outcome as partial response or progressive disease.
%decrease = TLAinitial −TLAﬁnal/TLAinitial ×100.
Table 3: Adverse events of patients after each vaccination.
1st vaccination 2nd vaccination 3rd vaccination 4th vaccination
P a t i e n t s pars s y s pars s y s pars s y s parss y s
0 1 xxxx
0 2 x x x x xx xx x
03 x x x x x 1,2,3
04 x x x x 4 x x
05 x x x
0 6 xx xx xx xx
0 7 x x 2 x xx xx x
Abbreviations
p, pain at vaccination site.
a, ardor at vaccination site.
r, redness at vaccination site.
s, swelling at vaccination site.
sys, systemic responses. 1-fever; 2-tremors; 3-Lower abdomen pain; 4-cramps.
at 3 months of followup after CIGB-228 vaccination. Col-
poscopic response was evidenced in six of seven patients
(85.7%), four of them (57.1%) complete and two (28.6%)
partial response (Table 2). Histological analyses indicated
that 57.1% of the patients (4/7) experienced full regression
while14.3%(1/7)hadhistologicalgradedownstaging.Stable
disease was observed in two patients (28.6%). Concomitant
negativization of HPV16 from the original lesion sites was
observed in three of the patients who had a complete
response (Table 1). None of the patients showed conﬁrmed
lesion recurrence during the 12-months, followup.
3.4. Immunologic Responses. PBMCs isolated from blood
samples drawn weekly before each vaccination (ﬁrst, second,
third, fourth) and one week after the last vaccination
were subjected to IFNγ ELISPOT analysis. Some preexisting
HPV16 T cell immunity that was E7 peptides 11–20, 82–
90 and 86–93-speciﬁc was detected in all patients (including
fourthpatientswhohadacompleteresponse);thisimmunity
was boosted by vaccination and coincided with enhanced
IFNγ production for all patients. The immunologic analysis
in which PBMCs were tested not only against the vaccination
CTL peptide 86–93 but also two additionally E7 peptides
(11–20,82–90)notonlymeasuredthepresenceofspeciﬁcally
a vaccine-induced T-cell response but also allowed the calcu-
lation of the strength of the immune response, operationally
deﬁned as a combination of the magnitude and breadth of
the T-cell response to all three peptide as intramolecular
epitope spreading. After the vaccination, all seven patients
respondedtopeptides 86–93and82–90.Sixofsevenpatients
were positive to peptide 11–20. The frequencies ranged
between one HPV-speciﬁc T cell among 100,000 PBMCs
up to 7 of 10,000 (see Table 4 for complete overview). The
peak of response for each patient reached after two or three
vaccinations, and the maximum response to HPV16 E7 86–
93 was more vigorous than against HPV16 E7 82–90 and
HPV16 E7 11–20 in the strength of response (Figure 3)a n d
in general are correlated with the clinical outcome.
These results suggest that the clinical eﬃcacy of a thera-
peutic HPV16 vaccine may be determined by its capacity to
induce strong and broad immune responses to the HPV16
oncoprotein E7.6 ISRN Obstetrics and Gynecology
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Figure 3: Immune response before and after vaccination. Note:
ELISPOT data as number of spots per 106 input CD8 cells is shown
on the ordinate, with paired patient samples (prevaccine, white
columns; postvaccine, black columns) indicated on the abscissa.
Each panel is shown for the individual peptide indicated at the top.
In each case, the maximum response postvaccination is shown.
4. Discussion
The HPV is an attractive target for a vaccine strategy, since
the HPV E7 transforming protein, which is critical for the
maintenance of a transformed state in animal model systems
and in humans, has been shown to encode epitopes that
Table 4: IFNγ ELISPOT analysis of PBMC before and after
vaccinations of patients.
Patients
01 02 03 04 05 06 07
Prevaccination
86–93 315 100 70 180 100 160 90
82–90 265 30 80 145 90 90 50
11–20 300 15 80 120 50 75 50
M1 85 85 60 75 50 85 60
After one vaccination
86–93 425 145 190 190 110 175 110
82–90 260 45 150 150 100 115 60
11–20 315 25 130 130 75 110 60
M1 90 90 75 75 45 90 55
After two vaccinations
86–93 540 305 125 530 320 460 220
82–90 435 185 85 360 220 420 100
11–20 335 115 115 315 230 425 105
M1 80 80 55 80 50 80 55
After three vaccinations
86–93 670 285 190 425 215 510 245
82–90 710 160 150 320 190 445 160
11–20 595 100 180 290 155 480 140
M1 80 80 55 60 55 80 55
After four vaccinations
86–93 655 195 275 450 190 450 200
82–90 725 140 160 335 180 375 110
11–20 550 105 165 300 130 410 85
M1 75 75 60 80 50 75 60
Note: The PBMCs were tested against three peptide of HPV16 E7 (86–93,
82–90 and 11–20). M1 was taken as positive control. In bold, the positive
responses (deﬁnition is described in Section 2) are depicted as number of
speciﬁc spots per 106 PBMCs.
bind to class I alleles and are recognized by T cells. Virus-
like particle vaccines have promise for primary prevention
of cervical intraepithelial neoplasia and cancer; however, it
is unlikely that they will impact on established disease or
preexistingintraepitheliallesions,sincethecapsidproteinsof
HPV are not expressed by neoplastic cells in high-grade CIN.
Women with HPV16 are more likely to develop CIN II/III
than those with other HPV types, and these data provide
a strong justiﬁcation for devising immunization strategies
against high-risk HPV type 16 to prevent progression of low-
grade CIN to high-grade disease, to treat high-grade CIN, to
prevent and treat the recurrence of high-grade CIN, and to
prevent the occurrence of invasive cervical cancer.
HPV-speciﬁc T cytolytic immune responses have been
demonstrated in patients with high-grade CIN and cer-
vical cancer [19]. Three peptides were deﬁned that were
immunogenic both in transgenic mice and in CTL induction
experiments using PBMCs from HLA-A2 healthy donors
derived from the 11–20, 82–90, and 86–93 amino acid
sequences [20]. E7-speciﬁc CTL cells have been generated
from the peripheral blood and lymph nodal tissue of HPV16
positive women with cervical dysplasia and cervical cancer
by in vitro restimulation with autologous antigen-presenting
cells pulsed with HPV16 E7 peptides [20, 21].
Trials to generate T cell reactivity against HPV16 E7 have
been carried out in women with cervical cancer or cervicalISRN Obstetrics and Gynecology 7
intraepithelial neoplasia. In previous reports, women with
stage IV cervical cancer were immunized with an E7 86–93
lipopeptide sequence, and only six patients mounted a weak
immune response against the E7 86–93 peptide sequence,
without evidence of clinical beneﬁt [22–24]. On the basis of
theclinicalrationaleofthat,womenwithalowerdiseasebur-
den and preinvasive disease are more logical candidates for
an antigen-speciﬁc immunotherapy than women with bulky
invasive disease, prior chemotherapy, poor performance
status, and profound immunosuppression; a phase I trial
with a similar CTL peptide vaccine has been conducted in
women with high-grade CIN. In that study, peptides binding
to HLA-A2 emulsiﬁed with Montanide ISA 51, an oil-based
adjuvant, were used for the treatment; 9/17 has evidence of
clinical response with modest rates of immunity. Although
the results obtained in that study were more optimistic
respect to the clinical beneﬁt, only 3 of 17 patients evaluated
had complete regression of their lesion pathologically [25].
Due to the low levels of immunity seen and lack of regression
observed, there is a perception that the peptide approach
has little promise for control of HPV-induced cancer. That
led many researchers to test vaccines based on E7 with
other formats such as viral vectors, DNA vaccines, and
fusion proteins [26–36]. Although there have been some
encouraging results with these vaccines, so far, there is no
clinical eﬃcacy study in patients with cervical neoplasia and
is still far to the approval of a therapeutic vaccine against
HPV.
In this work, immunotherapy with CIGB-228 containing
HPV16 E7 epitope adjuvated with VSSP is proven to be
safe. The maximal toxicity seen was grade 2 and consisted
of discomfort and swelling at the vaccination sites and low-
grade fever in the ﬁrst 24h after injection.
In the quoted studies, mostly, exact HLA class I-
bindingpeptideswereusedforimmunotherapyofmetastatic
melanoma, and the overall clinical results with such exact
HLA-ﬁtting peptides in patients with melanoma have been
very disappointing worldwide [37]. However, our preclinical
studies in mice indicated that immunization with exact
MHCclass-I-ﬁttingpeptideandVSSPissuperiortothatwith
peptide alone [11]. VSSP belong to the new generation of
adjuvants based on pathogen-related molecules identiﬁed as
“danger” signals that are recognized by the innate immune
system [38]. VSSP have the ability to activate mouse and
human DC, in vitro and in vivo, with the corresponding IL-
12p40/p70, TNF-α, and IL-6 production [9, 10]. Therefore,
VSSP is a potent adjuvant for DC activation and Th1
diﬀerentiation that provide the proper costimulatory context
f o rp r o d u c t i v ei m m u n er e s p o n s e s .
The rate of clinical response observed in this trial was
signiﬁcant although in the absence of randomized data and
control arm, it is possible that the regression of high-grade
C I Nm a yb ed u et os p o n t a n e o u sr e g r e s s i o n[ 39]. CIGB-228
vaccine treatment met the predetermined criteria of at least a
30% clinical response rate (CR+PR). The observed clinical
colposcopic response rate (85.7%), and histological response
rate (71.4%) in three months, was more than the estimated
spontaneous regression rate of high-grade CIN alone which
is estimated to be maximum 10% in 6 months.
Inthecurrentstudy,immuneresponseswereseentoclass
I-restricted epitopes of HPV16 E7 protein and regression
of CIN as well as diminution of grade of CIN have been
associated with the detection of CD8 T cell reactivity to
HPV16 E7 protein. There was no clear correlation between
HPV16 clearance and clinical response.
The small number of patients studied and the known
spontaneous regression rate of CIN prevents any deﬁnitive
conclusion as to the utility of the vaccine we tested. Only
in futures larger multi-institutional randomized study with
a placebo control arm will permit deﬁnitive conclusions to
be drawn about the eﬀectiveness of CIGB-228 vaccine in the
treatment of high-grade CIN.
The potential of peptides as therapeutic HPV vaccines
pass for the diﬃculties of using peptide antigens for treat-
ment of naturally occurring HPV-induced tumors are the
types of HPV causing the tumors (most frequently 16 and
18) and the genetic immunological makeup of the patient
(HLA type). However, it is possible to screen patients for the
typ e so fH P Vp r e s e n ta sw e l la sH L Atyp ea n di ti sp o s s i b l et o
create a patient-speciﬁc vaccine with the appropriate peptide
antigens, based on this information. Furthermore, these
vaccines are easily produced, are chemically stable, and are
devoid of oncogenic potential as well as free of bacterial/viral
contaminating substances, hereby avoiding the antigenic
competition often seen against viral vector-based vaccines
expressing tumor-associated antigens or HIV antigens [40–
43] or between simultaneously injected antigens such as in
the case with fusion protein or gene products [27, 44, 45].
5. Conclusion
In conclusion, our study shows that CIGB-228 vaccination
is safe and well tolerated. This vaccine generates promising
results based in the levels of immunity and clinical response.
It was found to induce robust IFNγ T-cell responses to
the HPV16 oncoprotein E7 in women with high-grade
CIN. CIGB-228 vaccination resulted in clinical activity, as
evidenced by the colposcopy, histology and the HPV clear-
ance. In patients with premalignant lesions, immunotherapy
with CIGB-228 vaccine is attractive and a trial to conﬁrm
therapeutic beneﬁt in such patients has been initiated.
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